Despite some travel challenges, we still filled the room for a sold-out event packed with thought-provoking discussions, candid insights, and dynamic exchanges about the forces shaping the drug channel. The 340B session was legendary!
We are grateful to everyone who took the stage to share their insights and to all who participated in making this event so impactful. A huge thank you to our speakers for sharing their expertise and unfiltered perspectives—and to everyone in the room for making the conversations so engaging.
I had the privilege of speaking on stage with leaders from AstraZeneca, Boehringer Ingelheim, Cardinal Health, 46Brooklyn, Nephron Research, and Prime Therapeutics.
And Mark Cuban wrapped up the first day with his unfiltered and highly entertaining take on U.S. healthcare. (Spoiler: He had a few opinions.)
Click here to see a selfie of Mark and me from the stage.
I also had the privilege of introducing the Drug Channels Institute team, seven members of whom attended the event.
Two of DCI’s newest team members—Tyler Novotny and Bryce Platt—each moderated panels.
You can find more photos by searching for #DCLF2026 on LinkedIn.
BTW, you won’t see any news stories about the DCLF. That’s because the media were not invited and the sessions were not recorded. No livestreams. No transcripts. You had to be in the room where it happened.😉
The DCLF will return in March 2027.
P.S. A special shoutout to the phenomenal HMP Global team, who delivered a truly first-class experience for nearly 400 attendees. Your hard work and dedication made this event unforgettable!
No comments:
Post a Comment